SP-10T1

SP-10T1 is an experimental drug candidate being developed by Scilex Holding Company. It is a novel, non-opioid, non-steroidal, and non-addictive formulation intended for the treatment of pain. While specific details regarding its molecular structure and precise mechanism of action are limited in public disclosures, it is part of Scilex's broader pipeline of non-opioid pain management therapies, which includes other candidates like SP-102 (SEMDEXA) and SP-103. The drug is designed to provide a safer alternative to traditional pain medications, particularly opioids and steroids, by utilizing a targeted delivery approach to minimize systemic side effects.